bevacizumab
Cold Chain RequiredFDA Approved, EMA Approved
Description
Bevacizumab is a recombinant humanized monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A). While primarily approved for various cancers, it is widely used off-label for neovascular age-related macular degeneration and other retinal diseases. The drug prevents angiogenesis and vascular permeability in the retina.
Indications & Therapeutic Use
metastatic colorectal cancer, non-small cell lung cancer, glioblastoma, renal cell carcinoma, off-label: neovascular age-related macular degeneration
Global Availability (12 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
bevacizumab
| Generic Name | bevacizumab |
| Brands | 1 brand available |
| Active Ingredient | bevacizumab |
| Drug Class | metastatic colorectal cancer |
| Manufacturer | Genentech/Roche |
| Dosage Forms | IV infusion, 25 mg/mL solution; intravitreal injection (off-label) |
| Medical Code | L01XC07 |
| Orphan Status | No |
| Cold Chain | Required |
| Lead Time | 14 days |
| Reg. Status | FDA Approved, EMA Approved |
| Clinical Trial | NCT00321594 |
| Countries | 12 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations13 Validated Nodes